Cargando…

miRNA-382-5p Suppresses the Expression of Farnesoid X Receptor to Promote Progression of Liver Cancer

BACKGROUND: The dysregulation of microRNAs (miRNAs) and hepatotoxicity due to the aberrant accumulation of bile acids (BAs) are notorious causes that predispose an individual to the development of hepatocellular carcinoma (HCC). Farnesoid X receptor (FXR), encoded by NR1H4 gene, has been identified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Xiaobo, Liu, Huiyang, Wei, Xiaoyun, Li, Lanqing, Lan, Linhua, Fan, Lili, Ma, Han, Liu, Lei, Zhou, Yun, Hou, Ruifang, Chen, Wei-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547345/ https://www.ncbi.nlm.nih.gov/pubmed/34712060 http://dx.doi.org/10.2147/CMAR.S324072

Ejemplares similares

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

LRP5 promotes cancer stem cell traits and chemoresistance in colorectal cancer
por: Nie, Xiaobo, et al.
Publicado: (2022)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis
por: Tschuck, Juliane, et al.
Publicado: (2023)

Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells
por: He, Jialin, et al.
Publicado: (2015)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
por: Jiang, Longying, et al.
Publicado: (2023)

Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma
por: Gong, Yihang, et al.
Publicado: (2021)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

miR-382 Contributes to Renal Tubulointerstitial Fibrosis by Downregulating HSPD1
por: Fang, Yi, et al.
Publicado: (2017)

Farnesoid X receptor is inhibited after ileum transposition in diabetic rats: its hypoglycemic effect
por: Chen, Weijie, et al.
Publicado: (2023)

Interplay of miRNAs and Canonical Wnt Signaling Pathway in Hepatocellular Carcinoma
por: Nie, Xiaobo, et al.
Publicado: (2018)

miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma
por: Feng, Jie, et al.
Publicado: (2017)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

miR-382 targeting PTEN-Akt axis promotes liver regeneration
por: Bei, Yihua, et al.
Publicado: (2015)

Circ-SAR1A Promotes Renal Cell Carcinoma Progression Through miR-382/YBX1 Axis
por: Zhao, Xiaolei, et al.
Publicado: (2020)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma
por: Xu, Meng, et al.
Publicado: (2014)

MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer
por: Yao, Hui, et al.
Publicado: (2019)

Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells by Inhibiting the Expression of c-FLIP
por: Chen, Zhong, et al.
Publicado: (2020)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
por: Ikpa, Pauline T., et al.
Publicado: (2019)

Investigating the Role of Farnesoid X Receptor in Heme Biosynthesis and Ductular Reaction
por: Dean, Angela E, et al.
Publicado: (2021)

Stimulation of the farnesoid X receptor promotes M2 macrophage polarization
por: Jaroonwitchawan, Thiranut, et al.
Publicado: (2023)

Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN
por: LIU, JUN, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tr8v491tkgs156ib9q8s9i2dkn